136 results
8-K
EX-10.1
n144h hwpm9hf
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
aqn3lr07mzru97v3c79n
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
i2smjcm06uc ync7
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
orcz4efkvhq
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
p5nzmk1o qyy
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
oox3i79
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
i363hdv
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
v7q6ud lf37k1h7ttk
30 May 23
Business combination disclosure
4:21pm
8-K
9raw2w 5m5f6zgh
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm
425
3jl37t35q2pf3zc1
22 May 23
Business combination disclosure
7:01am
8-K
gf0yr3p
22 May 23
Other Events
6:59am
8-K
EX-99.1
cjx39
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
wvjmjzs36mibe 64q
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
njqy nchy8qbiiv
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm